HPV 相关口咽癌的免疫治疗。
Immunotherapy in HPV-Related Oropharyngeal Cancers.
机构信息
Department of Hematology & Medical Oncology, Cleveland Clinic Taussig Cancer Institute, 10201 Carnegie Avenue, CA Building CA 6-150, Cleveland, OH, 44106, USA.
出版信息
Curr Treat Options Oncol. 2023 Mar;24(3):170-183. doi: 10.1007/s11864-023-01050-x. Epub 2023 Jan 31.
Abstract
Human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma (OPSCC) incidence has been increasing in recent decades. Treatment of the locally advanced HPV-related OPSCC includes a multidisciplinary approach. Immunotherapy with immune checkpoint inhibitors is used in the treatment of patients with recurrent/metastatic head and neck squamous cell carcinomas (HNSCC), including HPV-related OPSCC patients. There is increasing knowledge of the role of HPV in the tumor immune microenvironment. Therefore, HPV status of OPSCC plays an essential role in the design of immunotherapy clinical trials in both curative intent and metastatic settings. Moreover, HPV has become a potential therapeutic target, with vaccines and adoptive T-cell therapies being developed against HPV for the treatment of OPSCC. Several novel studies are designed to target HPV in combination with immune checkpoint inhibitors. Thus, HPV-related OPSCC remains a unique subgroup in the immunotherapy era.
摘要
近年来，人乳头瘤病毒（HPV）相关口咽鳞状细胞癌（OPSCC）的发病率一直在上升。局部晚期 HPV 相关 OPSCC 的治疗包括多学科方法。免疫检查点抑制剂免疫疗法用于治疗复发性/转移性头颈部鳞状细胞癌（HNSCC）患者，包括 HPV 相关 OPSCC 患者。人们越来越了解 HPV 在肿瘤免疫微环境中的作用。因此，HPV 状态在 HPV 相关 OPSCC 的治愈意图和转移性环境中的免疫疗法临床试验设计中起着至关重要的作用。此外，HPV 已成为一个潜在的治疗靶点，针对 HPV 开发疫苗和过继性 T 细胞疗法用于治疗 OPSCC。一些新的研究旨在将 HPV 与免疫检查点抑制剂联合靶向。因此，HPV 相关 OPSCC 在免疫治疗时代仍然是一个独特的亚组。
相似文献
1
Immunotherapy in HPV-Related Oropharyngeal Cancers.HPV 相关口咽癌的免疫治疗。
Curr Treat Options Oncol. 2023 Mar;24(3):170-183. doi: 10.1007/s11864-023-01050-x. Epub 2023 Jan 31.
2
The immune microenvironment of HPV-positive and HPV-negative oropharyngeal squamous cell carcinoma: a multiparametric quantitative and spatial analysis unveils a rationale to target treatment-naïve tumors with immune checkpoint inhibitors.HPV 阳性和 HPV 阴性口咽鳞状细胞癌的免疫微环境：一项多参数定量和空间分析揭示了用免疫检查点抑制剂靶向治疗初治肿瘤的合理性。
J Exp Clin Cancer Res. 2022 Sep 20;41(1):279. doi: 10.1186/s13046-022-02481-4.
3
Human Papilloma Virus Positive Oropharyngeal Squamous Cell Carcinoma and the Immune System: Pathogenesis, Immunotherapy and Future Perspectives.人乳头瘤病毒阳性口咽鳞状细胞癌与免疫系统：发病机制、免疫治疗及未来展望
Int J Mol Sci. 2024 Feb 28;25(5):2798. doi: 10.3390/ijms25052798.
4
Human papillomavirus (HPV) and oropharyngeal squamous cell carcinoma.人乳头瘤病毒（HPV）与口咽鳞状细胞癌
Presse Med. 2014 Dec;43(12 Pt 2):e429-34. doi: 10.1016/j.lpm.2014.08.010. Epub 2014 Nov 11.
5
Tumor-Derived Exosomes and the Role of Liquid Biopsy in Human Papillomavirus Oropharyngeal Squamous Cell Carcinoma.肿瘤衍生的外泌体与液活检在人乳头瘤病毒口咽鳞状细胞癌中的作用。
Cancer J. 2023;29(4):230-237. doi: 10.1097/PPO.0000000000000671.
6
Induction Chemotherapy in Low-Risk HPV+ Oropharyngeal Cancer.低危型 HPV 阳性口咽癌的诱导化疗。
Curr Treat Options Oncol. 2022 Jan;23(1):54-67. doi: 10.1007/s11864-022-00941-9. Epub 2022 Feb 16.
7
8
A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas.一项关于人乳头瘤病毒（HPV）与口腔及口咽鳞状细胞癌的临床病理参数及预后之间关联的系统性研究。
Cancer Med. 2017 May;6(5):910-917. doi: 10.1002/cam4.1045. Epub 2017 Apr 4.
9
The prognostic role of sex, race, and human papillomavirus in oropharyngeal and nonoropharyngeal head and neck squamous cell cancer.性别、种族和人乳头瘤病毒在口咽和非口咽头颈鳞状细胞癌中的预后作用。
Cancer. 2017 May 1;123(9):1566-1575. doi: 10.1002/cncr.30353. Epub 2017 Feb 27.
10
Prognostic implications of human papillomavirus status for patients with non-oropharyngeal head and neck squamous cell carcinomas.人乳头瘤病毒状态对非口咽头颈鳞状细胞癌患者的预后影响
J Cancer Res Clin Oncol. 2017 Nov;143(11):2341-2350. doi: 10.1007/s00432-017-2481-8. Epub 2017 Jul 27.
引用本文的文献
1
Immunotherapy Utilization Outcomes in Distantly Metastatic Head and Neck Squamous Cell Carcinoma.远处转移性头颈部鳞状细胞癌的免疫治疗应用结果
JAMA Otolaryngol Head Neck Surg. 2025 Jun 5. doi: 10.1001/jamaoto.2025.1351.
2
Inciting commensal human papillomavirus immunity to combat cancer.激发人体共生乳头瘤病毒免疫力以对抗癌症。
Trends Cancer. 2025 Jul;11(7):616-618. doi: 10.1016/j.trecan.2025.04.006. Epub 2025 May 1.
3
Vaccine-Based Immunotherapy for Oropharyngeal and Nasopharyngeal Cancers.基于疫苗的口咽癌和鼻咽癌免疫疗法
J Clin Med. 2025 Feb 11;14(4):1170. doi: 10.3390/jcm14041170.
4
Improved efficacy of therapeutic HPV DNA vaccine using intramuscular injection with electroporation compared to conventional needle and needle-free jet injector methods.与传统的针头注射和无针喷射注射器方法相比，采用肌肉注射联合电穿孔的治疗性人乳头瘤病毒（HPV）DNA疫苗疗效更佳。
Cell Biosci. 2024 Dec 25;14(1):154. doi: 10.1186/s13578-024-01338-x.
5
Intraperitoneal delivery of cannabidiol (CBD) and Δ-tetrahydocannabinol (THC) promotes papillomavirus infections in athymic nude mice.腹腔注射大麻二酚（CBD）和Δ-四氢大麻酚（THC）可促进无胸腺裸鼠的乳头瘤病毒感染。
Tumour Virus Res. 2024 Dec 16;19:200307. doi: 10.1016/j.tvr.2024.200307.
6
Potential Therapeutic Targets for the Treatment of HPV-Associated Malignancies.治疗人乳头瘤病毒相关恶性肿瘤的潜在治疗靶点
Cancers (Basel). 2024 Oct 14;16(20):3474. doi: 10.3390/cancers16203474.
7
Human Papillomavirus-Induced Chromosomal Instability and Aneuploidy in Squamous Cell Cancers.人乳头瘤病毒诱导的鳞状细胞癌中的染色体不稳定和非整倍体
Viruses. 2024 Mar 25;16(4):501. doi: 10.3390/v16040501.
8
Molecular aspects of cervical cancer: a pathogenesis update.宫颈癌的分子学研究进展：发病机制的最新情况
Front Oncol. 2024 Mar 19;14:1356581. doi: 10.3389/fonc.2024.1356581. eCollection 2024.
9
The combined HPV16-E2/E6/E7 T cell response in oropharyngeal cancer predicts superior survival.口咽癌中 HPV16-E2/E6/E7 T 细胞反应与生存预后相关。
Cell Rep Med. 2023 Nov 21;4(11):101262. doi: 10.1016/j.xcrm.2023.101262. Epub 2023 Nov 3.
10
Transcriptomic profiling of peripheral blood cells in HPV-associated carcinoma patients receiving combined valproic acid and avelumab.HPV 相关癌患者接受丙戊酸联合avelumab 治疗后外周血细胞的转录组分析。
Mol Oncol. 2024 May;18(5):1209-1230. doi: 10.1002/1878-0261.13519. Epub 2023 Sep 17.
本文引用的文献
1
Pembrolizumab versus cetuximab concurrent with radiotherapy in patients with locally advanced squamous cell carcinoma of head and neck unfit for cisplatin (GORTEC 2015-01 PembroRad): a multicenter, randomized, phase II trial.帕博利珠单抗与西妥昔单抗联合放疗用于不适合顺铂治疗的局部晚期头颈部鳞状细胞癌患者（GORTEC 2015 - 01 PembroRad）：一项多中心、随机、II期试验
Ann Oncol. 2023 Jan;34(1):101-110. doi: 10.1016/j.annonc.2022.10.006. Epub 2022 Oct 28.
2
Safety of Nivolumab Added to Chemoradiation Therapy Platforms for Intermediate and High-Risk Locoregionally Advanced Head and Neck Squamous Cell Carcinoma: RTOG Foundation 3504.纳武利尤单抗联合放化疗平台用于中高危局部晚期头颈部鳞状细胞癌的安全性：RTOG 基金会 3504 研究。
Int J Radiat Oncol Biol Phys. 2023 Mar 15;115(4):847-860. doi: 10.1016/j.ijrobp.2022.10.008. Epub 2022 Oct 11.
3
HPV-associated oropharyngeal cancer: epidemiology, molecular biology and clinical management.人乳头瘤病毒相关性口咽癌：流行病学、分子生物学及临床管理。
Nat Rev Clin Oncol. 2022 May;19(5):306-327. doi: 10.1038/s41571-022-00603-7. Epub 2022 Feb 1.
4
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer.人乳头瘤病毒相关头颈癌的免疫治疗方法
Cancers (Basel). 2021 Nov 23;13(23):5889. doi: 10.3390/cancers13235889.
5
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.实体瘤恶性肿瘤的过继细胞疗法：文献回顾与未来挑战。
J Immunother Cancer. 2021 Jul;9(7). doi: 10.1136/jitc-2021-002723.
6
NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer.NRG-HN003：帕博利珠单抗、顺铂和放射治疗用于病理高危头颈癌辅助治疗的I期及扩展队列研究。
Cancers (Basel). 2021 Jun 9;13(12):2882. doi: 10.3390/cancers13122882.
7
Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.CheckMate 358 试验中可切除的 HPV 阳性和 HPV 阴性头颈部鳞状细胞癌患者的新辅助纳武利尤单抗治疗。
J Immunother Cancer. 2021 Jun;9(6). doi: 10.1136/jitc-2021-002568.
8
Tumor Immunity and Immunotherapy for HPV-Related Cancers.肿瘤免疫与 HPV 相关癌症的免疫治疗。
Cancer Discov. 2021 Aug;11(8):1896-1912. doi: 10.1158/2159-8290.CD-20-1760. Epub 2021 May 14.
9
Avelumab plus standard-of-care chemoradiotherapy versus chemoradiotherapy alone in patients with locally advanced squamous cell carcinoma of the head and neck: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.avelumab 联合标准治疗放化疗对比单纯放化疗用于局部晚期头颈部鳞状细胞癌患者：一项随机、双盲、安慰剂对照、多中心、III 期临床试验。
Lancet Oncol. 2021 Apr;22(4):450-462. doi: 10.1016/S1470-2045(20)30737-3.
10
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers.针对转移性 HPV 相关上皮癌患者的 E7 靶向 TCR 工程化 T 细胞。
Nat Med. 2021 Mar;27(3):419-425. doi: 10.1038/s41591-020-01225-1. Epub 2021 Feb 8.
Zotero 插件